Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study

Background: Gastrointestinal bleeding (GIB) is a critical clinical emergency associated with high morbidity and mortality. The widespread use of antithrombotic agents, including antiplatelet and anticoagulant medications, has increased the incidence of GIB. Objectives: Our study aims to address this...

Full description

Saved in:
Bibliographic Details
Main Authors: Ding Peng, Huihong Zhai
Format: Article
Language:English
Published: SAGE Publishing 2025-06-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/17562848251342864
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849332886455451648
author Ding Peng
Huihong Zhai
author_facet Ding Peng
Huihong Zhai
author_sort Ding Peng
collection DOAJ
description Background: Gastrointestinal bleeding (GIB) is a critical clinical emergency associated with high morbidity and mortality. The widespread use of antithrombotic agents, including antiplatelet and anticoagulant medications, has increased the incidence of GIB. Objectives: Our study aims to address this gap by evaluating the impact of antithrombotic therapy on both 28-day mortality and rebleeding risk. Design: Retrospective cohort study using propensity score-based methods to address confounding. Methods: Data were extracted from three independent databases (MIMIC-IV, NWICU, and Xuanwu Hospital) spanning 2008–2022. inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics. Weighted logistic regression models assessed outcomes across antiplatelet, anticoagulant, and combination therapy subgroups. Results: After inverse probability of treatment weighting (IPTW) adjustment, the antithrombotic group maintained a significantly elevated rebleeding rate (19.9% vs 10.5%, p  < 0.001) and an increased risk of rebleeding (odds ratio (OR) = 2.118, 95% confidence interval (CI): 1.577–2.845, p  < 0.001). Conversely, the 28-day mortality was significantly lower in the antithrombotic group postadjustment (8.2% vs 12.5%, p  = 0.022; OR = 0.621, 95% CI: 0.412–0.935, p  = 0.023). Notably, early resumption of antithrombotic therapy (within 3 days) significantly increased the risk of mortality. Conclusion: Our study suggests that while antithrombotic therapy reduces 28-day mortality, it significantly increases rebleeding risk. Notably, the use of anticoagulants or combination therapy is linked to the highest rebleeding risk, compared to antiplatelets. Additionally, resuming antithrombotic therapy too early (i.e., within 3 days) may further elevate the risk of mortality.
format Article
id doaj-art-45d64dfc887645aeb370aa073d764277
institution Kabale University
issn 1756-2848
language English
publishDate 2025-06-01
publisher SAGE Publishing
record_format Article
series Therapeutic Advances in Gastroenterology
spelling doaj-art-45d64dfc887645aeb370aa073d7642772025-08-20T03:46:04ZengSAGE PublishingTherapeutic Advances in Gastroenterology1756-28482025-06-011810.1177/17562848251342864Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort studyDing PengHuihong ZhaiBackground: Gastrointestinal bleeding (GIB) is a critical clinical emergency associated with high morbidity and mortality. The widespread use of antithrombotic agents, including antiplatelet and anticoagulant medications, has increased the incidence of GIB. Objectives: Our study aims to address this gap by evaluating the impact of antithrombotic therapy on both 28-day mortality and rebleeding risk. Design: Retrospective cohort study using propensity score-based methods to address confounding. Methods: Data were extracted from three independent databases (MIMIC-IV, NWICU, and Xuanwu Hospital) spanning 2008–2022. inverse probability of treatment weighting (IPTW) was applied to balance baseline characteristics. Weighted logistic regression models assessed outcomes across antiplatelet, anticoagulant, and combination therapy subgroups. Results: After inverse probability of treatment weighting (IPTW) adjustment, the antithrombotic group maintained a significantly elevated rebleeding rate (19.9% vs 10.5%, p  < 0.001) and an increased risk of rebleeding (odds ratio (OR) = 2.118, 95% confidence interval (CI): 1.577–2.845, p  < 0.001). Conversely, the 28-day mortality was significantly lower in the antithrombotic group postadjustment (8.2% vs 12.5%, p  = 0.022; OR = 0.621, 95% CI: 0.412–0.935, p  = 0.023). Notably, early resumption of antithrombotic therapy (within 3 days) significantly increased the risk of mortality. Conclusion: Our study suggests that while antithrombotic therapy reduces 28-day mortality, it significantly increases rebleeding risk. Notably, the use of anticoagulants or combination therapy is linked to the highest rebleeding risk, compared to antiplatelets. Additionally, resuming antithrombotic therapy too early (i.e., within 3 days) may further elevate the risk of mortality.https://doi.org/10.1177/17562848251342864
spellingShingle Ding Peng
Huihong Zhai
Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study
Therapeutic Advances in Gastroenterology
title Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study
title_full Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study
title_fullStr Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study
title_full_unstemmed Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study
title_short Impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding: a multicenter retrospective cohort study
title_sort impact of antithrombotic therapy resumption in patients with gastrointestinal bleeding a multicenter retrospective cohort study
url https://doi.org/10.1177/17562848251342864
work_keys_str_mv AT dingpeng impactofantithrombotictherapyresumptioninpatientswithgastrointestinalbleedingamulticenterretrospectivecohortstudy
AT huihongzhai impactofantithrombotictherapyresumptioninpatientswithgastrointestinalbleedingamulticenterretrospectivecohortstudy